Related Experiment Video
Updated: Jan 22, 2026

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
Published on: June 5, 2020
A Time-Embedding Network Models the Ontogeny of 23 Hepatic Drug Metabolizing Enzymes
Matthew K Matlock1, Abhik Tambe1, Jack Elliott-Higgins1
1Department of Pathology and Immunology , Washington University in St. Louis , Saint Louis , Missouri 63110 , United States.
Insights
This study introduces time-embedding neural networks to model age-related changes in drug metabolism enzymes in children. This approach improves understanding of pediatric drug safety and potential toxicity risks.
Area of Science:
- Pharmacology
- Computational Biology
- Pediatric Medicine
Background:
- Pediatric patients face higher risks of adverse drug reactions due to limited safety data.
- Age-dependent changes in drug absorption, distribution, metabolism, and excretion complicate pediatric risk assessment.
- The ontogeny of drug metabolism enzymes significantly impacts age-dependent drug toxicity.
Purpose of the Study:
- To develop a computational model for predicting age-related variations in drug metabolism enzyme expression.
- To assess the utility of time-embedding neural networks in modeling enzyme ontogeny.
- To estimate age-dependent reactive metabolite exposure and identify potential toxicity mechanisms in pediatric populations.
Main Methods:
- Implementation of time-embedding neural networks to model the ontogeny of 23 drug metabolism enzymes.
- Utilizing the network to capture population-level variations in enzyme expression as a function of age.
- Combining the ontogeny model with additional data to estimate age-dependent reactive metabolite exposure.
Main Results:
- The time-embedding network accurately modeled the ontogeny of 23 drug metabolism enzymes.
- The model successfully recapitulated known demographic factors influencing CYP3A5 expression.
- It effectively captured nonlinear dynamics of CYP2D6 expression, outperforming standard neural networks.
- Age-dependent changes in reactive metabolite exposure for valproic acid and dextromethorphan were identified.
Conclusions:
- Time-embedding neural networks provide a robust method for modeling age-dependent drug metabolism enzyme expression in pediatric populations.
- This approach enhances the estimation of reactive metabolite exposure, aiding in the evaluation of drug toxicity risks.
- The findings suggest potential mechanisms for valproic acid toxicity and offer a valuable tool for pediatric drug safety research.
Abstract:
Pediatric patients are at elevated risk of adverse drug reactions, and there is insufficient information on drug safety in children. Complicating risk assessment in children, there are numerous age-dependent changes in the absorption, distribution, metabolism, and elimination of drugs. A key contributor to age-dependent drug toxicity risk is the ontogeny of drug metabolism enzymes, the changes in both abundance and type throughout development from the fetal period through adulthood. Critically, these changes affect not only the overall clearance of drugs but also exposure to individual metabolites. In this study, we introduce time-embedding neural networks in order to model population-level variation in metabolism enzyme expression as a function of age. We use a time-embedding network to model the ontogeny of 23 drug metabolism enzymes. The time-embedding network recapitulates known demographic factors impacting 3A5 expression. The time-embedding network also effectively models the nonlinear dynamics of 2D6 expression, enabling a better fit to clinical data than prior work. In contrast, a standard neural network fails to model these features of 3A5 and 2D6 expression. Finally, we combine the time-embedding model of ontogeny with additional information to estimate age-dependent changes in reactive metabolite exposure. This simple approach identifies age-dependent changes in exposure to valproic acid and dextromethorphan metabolites and suggests potential mechanisms of valproic acid toxicity. This approach may help researchers evaluate the risk of drug toxicity in pediatric populations.
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Hepatic Drug Excretion: Influencing Factors
Hepatic Drug Clearance: Role of Transporters
Time Course of Drug Effect
Hepatic Drug Excretion: Enterohepatic Cycling
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...

